PBPK Conference Basel 2026
PBPK Conference Basel 2026
April 20-23
April 20-23
PBPK Conference Basel 2026
April 20-23
PBPK Conference Basel 2026
21 - 24 April
·
Basel, Switzerland
PBPK Conference Basel 2026
21 - 24 April
·
Basel, Switzerland
The First International PBPK Conference brought together, for the very first time, a global community of researchers, clinicians, regulators, and industry scientists united by a single science: Physiologically Based Pharmacokinetic modelling. Held at the iconic Frank O. Gehry building on the Novartis Campus in Basel, this inaugural event marked a turning point for the PBPK field — giving it, at last, its own dedicated international forum.
Over four days, more than 50 speakers from leading institutions across academia, industry, and regulatory agencies — including the FDA, EMA, and MHRA — shared their latest findings, debated open questions, and forged new collaborations. From drug-drug interactions to special populations, from biologics to innovative computational approaches, the programme reflected the full scientific breadth and ambition of the PBPK community. This was not just a conference. It was a statement: PBPK science has come of age.
What the conference covered
Cutting-edge science across 7 thematic sessions
Participants engaged with the latest advances in PBPK modelling across drug-drug interactions, special populations, oral absorption, biomarkers and disease, biologics, regulatory science, and innovative computational approaches including machine learning and virtual twins.
Regulatory dialogue at the highest level
Connect with experienced professionals for guidance and support.
Rapid fire presentations and poster sessions
Emerging scientists and PhD candidates from institutions across Europe, North America, Asia, and Latin America presented their work in dynamic rapid fire sessions and poster viewings, ensuring that the next generation of PBPK scientists had a platform alongside established leaders.
What the conference covered
Cutting-edge science across 7 thematic sessions
Participants engaged with the latest advances in PBPK modelling across drug-drug interactions, special populations, oral absorption, biomarkers and disease, biologics, regulatory science, and innovative computational approaches including machine learning and virtual twins.
Regulatory dialogue at the highest level
Connect with experienced professionals for guidance and support.
Rapid fire presentations and poster sessions
Emerging scientists and PhD candidates from institutions across Europe, North America, Asia, and Latin America presented their work in dynamic rapid fire sessions and poster viewings, ensuring that the next generation of PBPK scientists had a platform alongside established leaders.
Why this conference mattered
For years, PBPK scientists convened as a small track within broader pharmacology or drug development conferences — never quite having the space to go deep, to debate freely, or to build the kind of community that the science deserved. The First International PBPK Conference changed that.
By creating a dedicated, independent forum, the International PBPK Nexus gave the field something it had long needed: a place where PBPK is not a sub-topic but the entire conversation. Where a PhD candidate from São Paulo and a Senior Director from AstraZeneca can sit in the same room, challenge the same assumptions, and leave with new collaborators. Where regulators and industry scientists can debate openly — not as adversaries, but as partners in advancing the science.
The success of this first edition confirmed what many in the community already believed: the PBPK field is ready for its own international home. And that home is now being built — one conference at a time.
Programme highlights by day
Day 1 : 21 April — Welcome & Opening
Registration, poster setup, and a Welcome Apéro & Networking event on the Novartis Campus, bringing together participants from around the world for the first time in an informal setting.
Day 2 : 22 April — Science, Regulation & Debate
Plenary sessions on PBPK, Drug-Drug Interactions, Rapid Fire presentations, and a major regulatory debate on PBPK vs PBBM and virtual control groups, with experts from industry and academia.
Day 3 : 23 April — Special Populations, Biomarkers & Biologics
Launch of the International PBPK Nexus, followed by sessions on special populations, biomarkers, disease modelling, and biologics, featuring leading pharmaceutical companies and research centres.
Day 4 : 24 April — Innovation & Oral Absorption
Sessions on emerging approaches including virtual twins, AI-assisted PBPK, and liquid biopsy-informed modelling, alongside advances in oral absorption and biopharmaceutics, concluding with closing remarks and future perspectives.
Programme highlights by day
Day 1 : 21 April — Welcome & Opening
Registration, poster setup, and a Welcome Apéro & Networking event on the Novartis Campus, bringing together participants from around the world for the first time in an informal setting.
Day 2 : 22 April — Science, Regulation & Debate
Plenary sessions on PBPK, Drug-Drug Interactions, Rapid Fire presentations, and a major regulatory debate on PBPK vs PBBM and virtual control groups, with experts from industry and academia.
Day 3 : 23 April — Special Populations, Biomarkers & Biologics
Launch of the International PBPK Nexus, followed by sessions on special populations, biomarkers, disease modelling, and biologics, featuring leading pharmaceutical companies and research centres.
Day 4 : 24 April — Innovation & Oral Absorption
Sessions on emerging approaches including virtual twins, AI-assisted PBPK, and liquid biopsy-informed modelling, alongside advances in oral absorption and biopharmaceutics, concluding with closing remarks and future perspectives.
The First International PBPK Conference brought together, for the very first time, a global community of researchers, clinicians, regulators, and industry scientists united by a single science: Physiologically Based Pharmacokinetic modelling. Held at the iconic Frank O. Gehry building on the Novartis Campus in Basel, this inaugural event marked a turning point for the PBPK field — giving it, at last, its own dedicated international forum.
Over four days, more than 50 speakers from leading institutions across academia, industry, and regulatory agencies — including the FDA, EMA, and MHRA — shared their latest findings, debated open questions, and forged new collaborations. From drug-drug interactions to special populations, from biologics to innovative computational approaches, the programme reflected the full scientific breadth and ambition of the PBPK community. This was not just a conference. It was a statement: PBPK science has come of age.
What the conference covered
Cutting-edge science across 7 thematic sessions
Participants engaged with the latest advances in PBPK modelling across drug-drug interactions, special populations, oral absorption, biomarkers and disease, biologics, regulatory science, and innovative computational approaches including machine learning and virtual twins.
Regulatory dialogue at the highest level
Connect with experienced professionals for guidance and support.
Rapid fire presentations and poster sessions
Emerging scientists and PhD candidates from institutions across Europe, North America, Asia, and Latin America presented their work in dynamic rapid fire sessions and poster viewings, ensuring that the next generation of PBPK scientists had a platform alongside established leaders.
Why this conference mattered
For years, PBPK scientists convened as a small track within broader pharmacology or drug development conferences — never quite having the space to go deep, to debate freely, or to build the kind of community that the science deserved. The First International PBPK Conference changed that.
By creating a dedicated, independent forum, the International PBPK Nexus gave the field something it had long needed: a place where PBPK is not a sub-topic but the entire conversation. Where a PhD candidate from São Paulo and a Senior Director from AstraZeneca can sit in the same room, challenge the same assumptions, and leave with new collaborators. Where regulators and industry scientists can debate openly — not as adversaries, but as partners in advancing the science.
The success of this first edition confirmed what many in the community already believed: the PBPK field is ready for its own international home. And that home is now being built — one conference at a time.
Programme highlights by day
Day 1 : 21 April — Welcome & Opening
Registration, poster setup, and a Welcome Apéro & Networking event on the Novartis Campus, bringing together participants from around the world for the first time in an informal setting.
Day 2 : 22 April — Science, Regulation & Debate
Plenary sessions on PBPK, Drug-Drug Interactions, Rapid Fire presentations, and a major regulatory debate on PBPK vs PBBM and virtual control groups, with experts from industry and academia.
Day 3 : 23 April — Special Populations, Biomarkers & Biologics
Launch of the International PBPK Nexus, followed by sessions on special populations, biomarkers, disease modelling, and biologics, featuring leading pharmaceutical companies and research centres.
Day 4 : 24 April — Innovation & Oral Absorption
Sessions on emerging approaches including virtual twins, AI-assisted PBPK, and liquid biopsy-informed modelling, alongside advances in oral absorption and biopharmaceutics, concluding with closing remarks and future perspectives.
